Navigation Links
ImmunoVaccine Technologies Patents DepoVax(TM) Vaccine Platform

HALIFAX, April 30 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, unveiled today its DepoVax(TM) platform, a novel depot vaccine delivery system used to increase the efficacy and strength of vaccines. IVT has filed additional patents to protect the DepoVax(TM) concept.

"The results from our preclinical studies demonstrate that DepoVax(TM) is highly effective with a single dose," remarked Marc Mansour, vice president of research and development at IVT. "DepoVax(TM) is superior to conventional vaccine formulations in its ability to raise strong cellular and humoral immune responses to a variety of antigens, a hallmark of IVT's vaccine formulations."

DepoVax(TM) has been tested in pandemic influenza and therapeutic cancer models. The research shows DepoVax(TM)-vaccines deliver effective, long lasting results with only one dose.

DepoVax(TM) vaccines are readily amenable to commercialization. They can be manufactured in large batches, and are well suited for large scale distribution and long term storage. DepoVax(TM) vaccines are packaged and stored in a dry form, ensuring the stability of antigens which can otherwise be unstable in aqueous formulations. DepoVax(TM) vaccines are also easy to administer by health care practitioners, an important consideration for immunization programs targeting infectious diseases in a population.

"Our patented technology offers a dramatic boost to the effectiveness of existing vaccines," said Randal Chase, president and CEO of IVT. "An effective and easy-to-administer DepoVax(TM) vaccine would be a valuable tool for health authorities dealing with a pandemic and we are planning to take this into the clinic as soon as possible."

About IVT

ImmunoVaccine Technologies Inc. is a private, clinical-stage, vaccine development company. Through its own biotech research and collaborations with partners, IVT creates vaccines with the potential to help save and improve lives around the world.

In December 2007, IVT signed a binding MOU to acquire Pennsylvania-based Immunotope Inc. The acquisition enables IVT to create an entire pipeline of proprietary therapeutic cancer and infectious-disease specific vaccines. In January 2008, IVT licensed its technology to Pfizer Animal health, marking a pivotal step in achieving its vision of delivering breakthrough vaccines.

SOURCE ImmunoVaccine Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ImmunoVaccine Technologies appoints the Honourable Michael Kirby as Chair
2. ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
3. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
4. Sticky nanotubes hold key to future technologies
5. Adoption of Spinal Nonfusion Technologies Doubled in One Year
6. Microchip Biotechnologies, Inc. Enters Into License Arrangement With GE Healthcare for Fundamental Microfluidic Patents
7. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
8. Pelikan Technologies and Lilly Form Alliance to Promote Diabetes Education
9. Emisphere Technologies To Hold Annual Stockholders Meeting on May 8, 2008
10. Neptune Technologies & Bioressources Inc. reports third quarter results and update on strategic milestones
11. Powersafe Technology Corp. Recapitalizes, Executes Merger Agreement with Amplification Technologies, and Invests in Amplification
Post Your Comments:
(Date:6/27/2016)... 2016  Sequenom, Inc. (NASDAQ: SQNM ), ... through the development of innovative products and services, announced ... United States denied its petition to review ... Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") are not ... the Supreme Court,s Mayo Collaborative Services v. Prometheus Laboratories ...
(Date:6/27/2016)... 2016  Liquid Biotech USA ... a Sponsored Research Agreement with The University of ... from cancer patients.  The funding will be used ... with clinical outcomes in cancer patients undergoing a ... be employed to support the design of a ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology:
(Date:3/23/2016)... WAKEFIELD, Massachusetts , March 23, 2016 ... kombiniert im Interesse erhöhter Sicherheit Gesichts- und ... Xura, Inc. (NASDAQ: MESG ... heute bekannt, dass das Unternehmen mit SpeechPro ... insbesondere aus der Finanzdienstleistungsbranche, wird die Möglichkeit ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
(Date:3/18/2016)... -- --> --> Competitive ... Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & Detection Systems ... security market and the continuing migration crisis in the ... has led visiongain to publish this unique report, which ... defence & security companies in the border security market ...
Breaking Biology News(10 mins):